CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that it has been selected to join the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to market open on Monday, May 23, 2011.
